Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this issue, Nagase and colleagues report the discovery of the first selective nonpeptidic orexin 2 receptor (OX2R) agonists. The discovery of these OX2R selective agonists opens up new avenues for therapies related to the activation of the orexin system, especially with respect to the treatment of sleep disorders such as narcolepsy.

Original publication

DOI

10.1021/acs.jmedchem.5b01394

Type

Journal article

Journal

J Med Chem

Publication Date

22/10/2015

Volume

58

Pages

7928 - 7930

Keywords

Animals, Benzamides, Humans, Orexin Receptors, Sulfonamides